Helicobacter Pylori Infections Pipeline Insight
DelveInsight’s, “Helicobacter Pylori Infections – Pipeline Insights, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Helicobacter Pylori Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Helicobacter Pylori Infections Understanding
Helicobacter Pylori Infections: Overview
Helicobacter pylori (H. pylori) is a gram-negative, microaerophilic, spiral-shaped and flagellated bacterium infecting about half the world’s population whose main reservoir is the human stomach. H. pylori possesses microbiological characteristics that allow it to survive in extremely adverse conditions such as the gastric acidic environment. H. pylori infection is the main cause of chronic gastritis and peptic ulcer disease. H. pylori has a determinant pathogenic role in the development of distal gastric adenocarcinoma and gastric mucosa associated lymphoid tissue (MALT) lymphoma; in fact, it can contribute to gastric carcinogenesis by stimulating gastric cell proliferation without counterbalancing with adequate apoptosis.
The symptoms of Helicobacter Pylori Infections include:
- Gastrointestinal bleeding
- Weight loss
- Frequent burping
H. pylori infection can be diagnosed by noninvasive methods or by endoscopic biopsy of the gastric mucosa; the selection of the appropriate test depends on the clinical setting. Noninvasive methods include the urea breath test, serologic tests, and stool antigen assays. The urea breath test relies on the abundant, H. pylori–derived urease activity in the stomach; it qualitatively detects active infection with a sensitivity and specificity of more than 90 percent. The test is indicated for the initial diagnosis of the infection and for follow-up of eradication therapy.
Antibiotics are combined with proton-pump inhibitors or ranitidine bismuth citrate and so-called triple therapies, combinations of one antisecretory agent with two antimicrobial agents for 7 to 14 days, have been extensively evaluated, and several regimens have been approved by the Food and Drug Administration (FDA). The combination of two or more antimicrobial agents increases rates of cure and reduces the risk of selecting for resistant H. pylori. The chief antimicrobial agents used in these regimens are amoxicillin, clarithromycin, metronidazole, tetracycline, and bismuth.
Gastroparesis Emerging Drugs
TAK-438 is an experimental drug that is a potassium- competitive acid blocker and is being studied in Phase III of clinical study. Originally, this compound was developed by Takeda and now licensed by Otsuka Pharmaceuticals and Phantom Pharmaceuticals.
CJ-12420 is a Phase 3 potassium- competitive acid blocker and H (+) and K (+) - exchanging ATPase inhibitors. It was originally developed by Pfizer but it is now licensed by HK inno.N, RaQualia Pharma, Shandong Luoxin Pharmaceutical.
Further product details are provided in the report……..
Helicobacter Pylori Infections: Therapeutic Assessment
This segment of the report provides insights about the different Helicobacter Pylori Infections drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Helicobacter Pylori Infections There are approx. 10+ key companies which are developing the therapies for Helicobacter Pylori Infections. The companies which have their Helicobacter Pylori Infections drug candidates in the most advanced stage, i.e. phase III include, Takeda.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Helicobacter Pylori Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Helicobacter Pylori Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Helicobacter Pylori Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Helicobacter Pylori Infections drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Helicobacter Pylori Infections R&D. The therapies under development are focused on novel approaches to treat/improve Helicobacter Pylori Infections.
- In April 2020, Meridian Bioscience, Inc. a provider of diagnostic testing solutions and life science raw materials, has completed its previously announced acquisition of Exalenz Bioscience Ltd., the Modiin, Israel based provider of the BreathID Breath Test Systems, a urea breath test platform for the detection of Helicobacter pylori.
Helicobacter Pylori Infections Report Insights
- Helicobacter Pylori Infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Helicobacter Pylori Infections Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Helicobacter Pylori Infections drugs?
- How many Helicobacter Pylori Infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Helicobacter Pylori Infections?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Helicobacter Pylori Infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Helicobacter Pylori Infections and their status?
- What are the key designations that have been granted to the emerging drugs?
- Servatus Biopharmaceuticals